Biomaterial Database

[Intra-arterial chemotherapy for the treatment of advanced hepatocellular carcinoma through implantable port (reservoir)]. 1994

T Motohara, and Z Ozawa, and S Morita

Dept. of Radiology, Kochi Municipal Central Hospital.

In this study, we evaluated the effectiveness of the arterial infusion chemotherapy through an implantable port for the treatment of advanced hepatocellular carcinoma. The chemotherapy comprised weekly or biweekly administrations of epi-ADM combined with 5-FU and MMC. The patients were divided into 4 groups as follows: 1) 37 patients treated mainly by repeat transcatheter arterial embolization (TAE) (TAE group); 2) 16 patients treated by arterial infusion chemotherapy through implantable port after TAE (TAE-RV group); 3) 9 patients with no indication for TAE treated by one-shot arterial infusion chemotherapy (one-shot group); and 4) 13 patients with no indication for TAE treated by arterial infusion chemotherapy through an implantable port (RV group). The median survival after the complete courses of TAE was 23 weeks in the TAE group, and 59 weeks in the TAE-RV group. There was a statistically significant difference in median survival time between the TAE group and the TAE-RV group (p < 0.01). On the other hand, the median survival time after the initial administration of an anticancer agent was 9 weeks in the one-shot group and 24 weeks in the RV group. There was also a statistically significant difference in median survival between the one-shot group and the RV group (p < 0.01). In the RV group, the 30-day mortality after the initial arterial infusion chemotherapy was 23.1% (3 patients). Two of these 3 patients showed a poor clinical status with uncontrollable ascites at the beginning of this study. In conclusion, arterial infusion chemotherapy through implantable port was evaluated as effective for the treatment of advanced hepatocellular carcinoma in patients with no indication for TAE, but the indication of this therapy remained subject for further evaluation.

UI	MeSH Term	Description	Entries
D007261	Infusions, Intra-Arterial	Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.	Infusions, Regional Arterial,Infusions, Intra Arterial,Infusions, Intraarterial,Arterial Infusion, Intra,Arterial Infusion, Regional,Arterial Infusions, Intra,Arterial Infusions, Regional,Infusion, Intra Arterial,Infusion, Intra-Arterial,Infusion, Intraarterial,Infusion, Regional Arterial,Intra Arterial Infusion,Intra Arterial Infusions,Intra-Arterial Infusion,Intra-Arterial Infusions,Intraarterial Infusion,Intraarterial Infusions,Regional Arterial Infusion,Regional Arterial Infusions
D007269	Injections, Intra-Arterial	Delivery of drugs into an artery.	Injections, Intraarterial,Intra-Arterial Injections,Intraarterial Injections,Injection, Intra-Arterial,Injection, Intraarterial,Injections, Intra Arterial,Intra Arterial Injections,Intra-Arterial Injection,Intraarterial Injection
D008113	Liver Neoplasms	Tumors or cancer of the LIVER.	Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D004334	Drug Administration Schedule	Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.	Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260	Female		Females
D005472	Fluorouracil	A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.	5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006528	Carcinoma, Hepatocellular	A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man